Rybelsus vs Ozempic: both are semaglutide for type 2 diabetes. Rybelsus is a tablet taken once a day on an empty stomach; Ozempic is an injection taken once a week. In their trial programs, Ozempic 1 mg lowered HbA1c by about 1.5 to 1.8 points and Rybelsus 14 mg by about 1.0 to 1.4 points, and the injection also produced more weight loss.[4] A newer, better-absorbed tablet sold as Ozempic tablets (1.5, 4 and 9 mg) now shares Rybelsus’s label.[1] Earlier in 2026, Novo Nordisk stopped marketing the pill under the Rybelsus name and began marketing it as the pill form of Ozempic or Wegovy, depending on the dose.[14]
See our semaglutide profile for the drug’s full history.
Rybelsus vs Ozempic at a glance
| Rybelsus | Ozempic injection | |
|---|---|---|
| Form | Daily tablet[1] | Weekly injection under the skin[2] |
| Doses | 3 mg (start), 7 mg, 14 mg[1] | 0.25 mg (start), 0.5, 1, 2 mg[2] |
| How much is absorbed | About 0.4% to 1%[1] | About 89%[2] |
| Food rules | Empty stomach, up to 4 oz water, wait 30 minutes[1] | Any time, with or without food[2] |
| HbA1c drop in its trials | About 1.0 to 1.4 points (14 mg)[4] | About 1.5 to 1.8 points (1 mg)[4] |
| Heart indication | Yes (SOUL)[1] | Yes (SUSTAIN-6)[2] |
| Kidney indication | No | Yes (FLOW)[2] |
| Weight-loss approval | No | No |
What changed with the new semaglutide tablets
The current tablet label, revised in January 2026, covers two tablet products:[1]
| Rybelsus | Ozempic tablets | Role |
|---|---|---|
| 3 mg | 1.5 mg | Starting dose for 30 days (not effective for blood sugar) |
| 7 mg | 4 mg | First maintenance dose |
| 14 mg | 9 mg | Higher maintenance dose |
The newer tablets deliver similar blood levels with less drug, because about 1% to 2% of each dose is absorbed versus 0.4% to 1% for Rybelsus. The label says the two products are not substitutable milligram for milligram; the rows above are the label’s switching pairs.[1] FDA’s records list a “new dosing regimen” approval for this application in December 2024 and a new indication in October 2025.[3] Both tablets were approved based on the Rybelsus trials.[1]
The brand name changed too. A July 2026 federal court order notes that Novo Nordisk stopped marketing the semaglutide pill as “Rybelsus” earlier in 2026 and now markets it as Ozempic or Wegovy tablets, depending on the dose.[14] Rybelsus 3, 7 and 14 mg are still listed on the FDA label. If you have been taking Rybelsus, your prescriber or pharmacist can confirm which tablet and strength to use next; the table above shows the label’s switching pairs.[1]
How the pill works without being digested
Semaglutide is a peptide, which stomach acid and enzymes normally destroy. The tablets contain an absorption enhancer called SNAC, which helps semaglutide cross the stomach lining. Absorption happens mostly in the stomach, which is why the label requires:[1]
- taking it first thing in the morning on an empty stomach
- swallowing it whole with no more than 4 ounces (about half a cup) of plain water
- waiting at least 30 minutes before food, other drinks or other pills
Even then, absorption varies more from person to person than with the injection. Our guide to oral vs injectable semaglutide explains this in more detail.
PIONEER vs SUSTAIN: what the trials showed
The two drugs were never compared directly. Here are similar trials from each program:
| Trial | Drug | Weeks | HbA1c change | Weight change |
|---|---|---|---|---|
| PIONEER 1 | Rybelsus 7 / 14 mg | 26 | −1.2 / −1.4 (placebo −0.3)[1] | −2.3 / −3.7 kg (placebo −1.4)[1] |
| SUSTAIN 1 | Ozempic 0.5 / 1 mg | 30 | −1.45 / −1.55 (placebo −0.02)[5] | −3.7 / −4.5 kg[5] |
| PIONEER 4 | Rybelsus 14 mg vs liraglutide | 26 | −1.2 vs −1.1[6] | −4.4 vs −3.1 kg[6] |
| SUSTAIN 7 | Ozempic 1 mg vs dulaglutide 1.5 mg | 40 | −1.8 vs −1.4[7] | −6.5 vs −3.0 kg[7] |
| SUSTAIN FORTE | Ozempic 2 mg | 40 | −2.1[8] | −6.4 kg[8] |
A review of both programs found injectable semaglutide beat every active comparator tested on weight, while oral semaglutide beat sitagliptin and liraglutide and matched empagliflozin.[4]
Heart and kidney protection
- Rybelsus (SOUL): in 9,650 people with type 2 diabetes and heart disease, kidney disease or both, heart attack, stroke or cardiovascular death occurred in 12.0% on oral semaglutide versus 13.8% on placebo over about 4 years.[9] This led to the tablets’ heart-risk indication.[1]
- Ozempic (SUSTAIN-6): those events fell from 8.9% to 6.6%.[10]
- Ozempic (FLOW): major kidney events fell by 24% in people with type 2 diabetes and chronic kidney disease, an indication the tablets do not have.[11][2]
Side effects
Both labels list the same core side effects: nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation.[1][2] In PIONEER 4, adverse events of any kind affected 80% on Rybelsus and 74% on liraglutide.[6] Both carry the boxed warning about thyroid C-cell tumors in rodents.[1][2]
Weight loss on Rybelsus vs Ozempic
Neither drug is approved for weight loss, but both lower weight in people with type 2 diabetes. In the trials above, Rybelsus 14 mg lowered weight by about 3.7 to 4.4 kg over 26 weeks, while Ozempic 1 mg lowered it by about 4.5 to 6.5 kg over 30 to 40 weeks, and Ozempic 2 mg by 6.4 kg.[1][6][5][7][8] The higher-dose semaglutide products made for weight management are Wegovy injections and the 25 mg Wegovy pill; see Wegovy vs Ozempic.
Taking other medicines with Rybelsus
Because the tablet must be taken alone, any other morning pills have to wait at least 30 minutes.[1] The label also notes that semaglutide tablets raise blood levels of levothyroxine, a thyroid hormone, so thyroid levels may need monitoring.[1] Ozempic injections have no timing rules around meals or other medicines, although slowed stomach emptying can affect how some oral drugs are absorbed.[2]
Switching between Ozempic and Rybelsus
The tablet label gives one switching route from the injection:[1]
- Ozempic 0.5 mg weekly → Rybelsus 7 mg or 14 mg daily, or Ozempic tablets 4 mg or 9 mg daily, starting one week after the last injection.
- Rybelsus ↔ Ozempic tablets: after the first 30 days, 7 mg matches 4 mg and 14 mg matches 9 mg; start the new tablet the day after stopping the old one.
There is no labeled conversion from Ozempic 1 mg or 2 mg to a tablet. Your prescriber decides the dose.
Cost
In October 2026, NovoCare listed self-pay Ozempic injection at $349 a month for 0.25 to 1 mg and $499 for 2 mg, and self-pay Ozempic tablets starting at $149 a month for the 1.5 mg dose; tablet prices vary by dose.[13] Commercial savings cards can reduce copays to as little as $25.[13] See Ozempic cost without insurance.
Prices checked October 2026. They change often; confirm with NovoCare or your plan.
Which is right for you?
- Prefer no needles and can keep a strict morning routine: a semaglutide tablet.
- Want the largest blood sugar and weight effect, or need kidney protection: Ozempic injection.
- Want semaglutide for weight loss without diabetes: see Wegovy vs Ozempic instead.
